sunitinib + trastuzumab

Sunitinib + trastuzumab is a combination therapy investigated for the treatment of HER2-positive advanced breast cancer. Sunitinib is an orally administered small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor that blocks several kinases involved in tumor growth, angiogenesis, and metastatic progression, including platelet-derived growth factor receptors (PDGFRs), vascular endothelial growth factor receptors (VEGFRs), KIT (CD117), RET, CSF-1R, and FLT3. Trastuzumab is a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2/ERBB2), inhibiting its signaling and mediating antibody-dependent cellular cytotoxicity. The combination has demonstrated antitumor activity in patients with HER2-positive advanced breast cancer, particularly those who were treatment-naïve or had only received prior adjuvant therapy. However, sunitinib is not approved for this indication as it did not meet primary endpoints in phase III trials for advanced breast cancer[1][2][8].